About Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626
Debt
Debt-to-Equity Ratio0.15%
Current Ratio4.90%
Quick Ratio4.90%
Price-To-Earnings
Trailing P/E Ratio-3.48
Forward P/E Ratio-2.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$32.10 million
Price / Sales9.75
Cash FlowN/A
Price / CashN/A
Book Value$1.50 per share
Price / Book5.13
Profitability
EPS (Most Recent Fiscal Year)($2.21)
Net Income$-89,380,000.00
Net Margins-278.44%
Return on Equity-103.46%
Return on Assets-41.45%
Miscellaneous
Employees138
Outstanding Shares40,650,000
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics Inc (NASDAQ:MCRB) posted its earnings results on Thursday, March, 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The biotechnology company earned $3.06 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 278.44% and a negative return on equity of 103.46%. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
8 brokers have issued 1 year target prices for Seres Therapeutics' stock. Their predictions range from $16.00 to $20.00. On average, they expect Seres Therapeutics' stock price to reach $18.8571 in the next year. View Analyst Ratings for Seres Therapeutics.
What are Wall Street analysts saying about Seres Therapeutics stock?
Here are some recent quotes from research analysts about Seres Therapeutics stock:
- 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/14/2018)
- 2. Cowen Inc analysts commented, "Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with." (10/2/2017)
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX) and Athenex (ATNX).
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer (Age 60)
- Eric D. Shaff, Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer (Age 42)
- John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing (Age 56)
- David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development (Age 59)
- Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary (Age 62)
- Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President (Age 64)
- Noubar B. Afeyan, Lead Independent Director (Age 55)
- Willard H. Dere M.D., Director (Age 63)
- Dennis A. Ausiello M.D., Independent Director (Age 71)
- Gregory Behar, Independent Director (Age 49)
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
Has Seres Therapeutics been receiving favorable news coverage?
News headlines about MCRB stock have trended somewhat positive recently, Accern reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seres Therapeutics earned a coverage optimism score of 0.21 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 43.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Seres Therapeutics' major shareholders?
Seres Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NESTLE HEALTH SCIENCE US HOLDINGS, INC. (16.97%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $7.70.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $314.21 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe.
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.
MarketBeat Community Rating for Seres Therapeutics (MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Seres Therapeutics (NASDAQ:MCRB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Seres Therapeutics in the last 12 months. Their average twelve-month price target is $18.8571, suggesting that the stock has a possible upside of 144.90%. The high price target for MCRB is $20.00 and the low price target for MCRB is $16.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.8571 | $18.8571 | $18.75 | $18.75 |
| Price Target Upside: | 144.90% upside | 73.48% upside | 72.49% upside | 72.49% upside |
Seres Therapeutics (NASDAQ:MCRB) Consensus Price Target History
Seres Therapeutics (NASDAQ:MCRB) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Seres Therapeutics (NASDAQ:MCRB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Seres Therapeutics (NASDAQ MCRB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 79.02%
Seres Therapeutics (NASDAQ MCRB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/26/2018 | David N Cook | Insider | Sell | 1,738 | $11.02 | $19,152.76 | 141,673 |  |
| 12/19/2017 | John G Aunins | Insider | Sell | 1,623 | $10.14 | $16,457.22 | 61,060 | |
| 8/29/2016 | John G Aunins | Insider | Sell | 9,390 | $10.87 | $102,069.30 | 192,125 | |
| 7/28/2016 | Michele Trucksis | Insider | Sell | 4,156 | $35.18 | $146,208.08 | 4,156 | |
| 7/27/2016 | Michele Trucksis | Insider | Sell | 38,064 | $35.14 | $1,337,568.96 | 38,064 | |
| 7/25/2016 | John G Aunins | Insider | Sell | 9,390 | $34.18 | $320,950.20 | 220,155 | |
| 7/6/2016 | Roger Pomerantz | CEO | Sell | 88,211 | $29.45 | $2,597,813.95 | 236,468 | |
| 7/1/2016 | Roger Pomerantz | CEO | Sell | 56,789 | $29.81 | $1,692,880.09 | 240,481 | |
| 6/30/2016 | Eric D Shaff | CFO | Sell | 4,533 | $29.54 | $133,904.82 | 4,533 | |
| 6/28/2016 | Eric D Shaff | CFO | Sell | 5,001 | $28.28 | $141,428.28 | 3,334 | |
| 6/27/2016 | John G Aunins | EVP | Sell | 9,390 | $27.23 | $255,689.70 | 32,655 | |
| 6/2/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | 136,673 | |
| 6/2/2016 | Roger Pomerantz | CEO | Sell | 74,049 | $32.52 | $2,408,073.48 | 257,741 | |
| 6/1/2016 | David N Cook | EVP | Sell | 16,000 | $29.43 | $470,880.00 | 144,673 | |
| 6/1/2016 | Roger Pomerantz | CEO | Sell | 70,951 | $30.51 | $2,164,715.01 | 254,643 | |
| 5/25/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 1,000,000 | $27.60 | $27,600,000.00 | | |
| 5/24/2016 | Roger Pomerantz | CEO | Sell | 9,801 | $30.00 | $294,030.00 | 193,493 | |
| 5/6/2016 | Roger Pomerantz | CEO | Sell | 8,507 | $24.31 | $206,805.17 | 31,234 | |
| 5/5/2016 | Roger Pomerantz | CEO | Sell | 59,325 | $26.13 | $1,550,162.25 | 51,325 | |
| 5/3/2016 | Roger Pomerantz | CEO | Sell | 67,367 | $28.70 | $1,933,432.90 | 66,414 | |
| 4/25/2016 | John G Aunins | EVP | Sell | 18,640 | $31.94 | $595,361.60 | 56,060 | |
| 4/7/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | 160,673 | |
| 4/7/2016 | Roger Pomerantz | CEO | Sell | 9,212 | $30.00 | $276,360.00 | 24,439 | |
| 4/4/2016 | David N Cook | EVP | Sell | 61,000 | $26.16 | $1,595,760.00 | 183,023 | |
| 4/4/2016 | Eric D Shaff | CFO | Sell | 6,568 | $28.85 | $189,486.80 | 6,568 | |
| 4/4/2016 | Roger Pomerantz | CEO | Sell | 135,788 | $27.20 | $3,693,433.60 | 113,690 | |
| 3/31/2016 | Eric D Shaff | CFO | Sell | 7,663 | $26.30 | $201,536.90 | 7,663 | |
| 3/28/2016 | Eric D Shaff | CFO | Sell | 5,473 | $24.07 | $131,735.11 | 5,473 | |
| 3/28/2016 | John G Aunins | EVP | Sell | 9,390 | $23.89 | $224,327.10 | 74,700 | |
(Data available from 1/1/2013 forward)
Seres Therapeutics (NASDAQ MCRB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Seres Therapeutics (MCRB) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 8:31 PM |
 | Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 17 at 6:03 PM |
| Seres Therapeutics (MCRB) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 AM |
| Seres Therapeutics (MCRB) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 14 at 8:35 PM |
| Seres Therapeutics (MCRB) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - April 13 at 11:03 AM |
| Seres Therapeutics (MCRB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 10:46 PM |
| $3.00 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter
www.americanbankingnews.com - April 12 at 5:05 AM |
| Seres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.74 Per Share
www.americanbankingnews.com - April 10 at 3:13 AM |
 | Seres Therapeutics wins dismissal of investor lawsuit over drug study
www.reuters.com - April 3 at 5:40 PM |
| Seres Therapeutics Inc (MCRB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 31 at 1:36 AM |
| Zacks Investment Research Lowers Seres Therapeutics (MCRB) to Hold
www.americanbankingnews.com - March 30 at 10:02 PM |
| Seres Therapeutics (MCRB) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 28 at 10:44 AM |
| Zacks: Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - March 26 at 8:04 AM |
| BidaskClub Lowers Seres Therapeutics (MCRB) to Sell
www.americanbankingnews.com - March 25 at 9:51 AM |
| Edited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 6:27 PM |
| Zacks Investment Research Upgrades Seres Therapeutics (MCRB) to "Hold"
www.americanbankingnews.com - March 18 at 10:32 AM |
| FY2018 EPS Estimates for Seres Therapeutics Inc (MCRB) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - March 14 at 10:28 AM |
| Research Analysts Issue Forecasts for Seres Therapeutics Inc's FY2019 Earnings (MCRB)
www.americanbankingnews.com - March 13 at 3:07 PM |
| Seres Therapeutics (MCRB) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 11 at 2:07 PM |
| Seres Therapeutics (MCRB) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - March 10 at 5:28 PM |
| Seres Therapeutics (MCRB) Releases Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 9 at 4:15 PM |
 | Seres Therapeutics to Present at Two Upcoming March Conferences - Business Wire (press release)
www.businesswire.com - March 9 at 8:12 AM |
| Seres Therapeutics to Present at Two Upcoming March Conferences
finance.yahoo.com - March 9 at 8:12 AM |
| Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates - Business Wire (press release)
www.businesswire.com - March 8 at 8:15 AM |
| Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
finance.yahoo.com - March 8 at 8:15 AM |
| Seres Therapeutics Inc to Host Earnings Call
finance.yahoo.com - March 8 at 8:15 AM |
| Seres Therapeutics Inc (MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - March 8 at 2:02 AM |
| Seres Therapeutics (MCRB) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM |
| Seres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.73 Per Share
www.americanbankingnews.com - March 6 at 9:22 PM |
| Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 6 at 1:36 AM |
| Citadel Advisors LLC Buys New Position in Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - March 3 at 5:20 AM |
| Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and ... - Business Wire (press release)
www.businesswire.com - March 2 at 8:09 AM |
| Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
finance.yahoo.com - March 2 at 8:09 AM |
| Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller — Future Expectations, Projections Moving into 2018
finance.yahoo.com - February 26 at 8:11 AM |
| ARK Investment Management LLC Acquires 732,579 Shares of Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - February 26 at 5:12 AM |
| Seres Therapeutics (MCRB) Upgraded at BidaskClub
www.americanbankingnews.com - February 24 at 4:30 PM |
| Seres Therapeutics Inc (MCRB) Expected to Post Earnings of -$0.73 Per Share
www.americanbankingnews.com - February 18 at 5:08 AM |
| Financial Analysis: Seres Therapeutics (MCRB) versus Its Rivals
www.americanbankingnews.com - February 5 at 9:48 AM |
| Zacks: Analysts Anticipate Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - February 3 at 6:56 AM |
| Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
finance.yahoo.com - January 31 at 9:03 AM |
| David N. Cook Sells 1,738 Shares of Seres Therapeutics Inc (MCRB) Stock
www.americanbankingnews.com - January 30 at 9:18 PM |
| Seres Therapeutics (MCRB) and Its Competitors Head-To-Head Survey
www.americanbankingnews.com - January 18 at 3:28 PM |
| Seres Therapeutics Inc (MCRB) Expected to Announce Quarterly Sales of $3.00 Million
www.americanbankingnews.com - January 17 at 2:50 PM |
| Critical Contrast: Verastem (VSTM) vs. Seres Therapeutics (MCRB)
www.americanbankingnews.com - January 15 at 1:16 PM |
| Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 15 at 1:38 AM |
| Comparing Seres Therapeutics (MCRB) & The Competition
www.americanbankingnews.com - January 14 at 1:42 PM |
| Financial Comparison: Catabasis Pharmaceuticals (CATB) versus Seres Therapeutics (MCRB)
www.americanbankingnews.com - January 8 at 11:06 PM |
| Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)
www.americanbankingnews.com - January 8 at 8:40 PM |
 | Seres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for ... - StreetInsider.com
www.streetinsider.com - January 5 at 4:50 PM |
| Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:45 AM |
Seres Therapeutics (NASDAQ:MCRB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Seres Therapeutics (NASDAQ:MCRB) Income Statement, Balance Sheet and Cash Flow Statement
Seres Therapeutics (NASDAQ MCRB) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
